Hikal Limited Announces Audited Standalone Financial Results for the Fourth Quarter and Year Ended March 31, 2017 and Consolidated Earnings Results for the Year Ended March 31, 2017
May 11, 2017 at 01:47 am
Share
Hikal Limited announced audited standalone financial results for the fourth quarter and year ended March 31, 2017 and consolidated earnings results for the year ended March 31, 2017. For the year, the company reported standalone net sales up 9.5% to INR 10,139 as compared to INR 9,257 million in the corresponding period of the previous year. EBITDA up 9.1% to INR 1,974 million as compared to INR 1,809 million in the corresponding period of the previous year. Net Profit up 61.7% to INR 668 million as compared to INR 413 million in the corresponding period of the previous year. Diluted per share was INR 16.54 against INR 13.21 a year ago.
For the quarter, the company reported standalone net sales up 6.8% to INR 3,096 million as compared to INR 2,898 million in the corresponding period of the previous year. EBITDA down 4.3% to INR 570 million as compared to INR 596 million in the corresponding period of the previous year. Net Profit up 23.3% to INR 274 million as compared to INR 223 million in the corresponding period of the previous year. Diluted per share was INR 5.42 against INR 4.82 a year ago.
For year, the company reported consolidated net profit of INR 638.9 million against INR 411.9 million a year ago. Diluted per share was INR 16.18 against INR 13.20 a year ago.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
Hikal Limited Announces Audited Standalone Financial Results for the Fourth Quarter and Year Ended March 31, 2017 and Consolidated Earnings Results for the Year Ended March 31, 2017